Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.
Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. · 2010
Read Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. by Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3248123.txt.
Introduction
Desmond Powe and colleagues reported that breast cancer patients taking beta-blockers fared strikingly better, in this 2010 study in Oncotarget. Laboratory work had shown the beta-blocker propranolol can stop a stress hormone from driving breast cancer cells to migrate. The team checked medical records of more than four hundred women with operable breast cancer followed for over ten years.
Women already taking beta-blockers for blood pressure before diagnosis developed fewer metastases and recurrences and stayed disease-free longer than both other blood-pressure patients and women without hypertension. Their risk of metastasis was cut by well over half, and their risk of dying of breast cancer over ten years fell by about seventy percent. The authors call this proof of principle and ask for larger studies leading to randomized trials, in breast and other cancers.
Catalog record
| CREATOR | Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival By Desmond G. Powe, Melanie J. Voss, Kurt S. Zänker, Hany O. Habashy, Andrew R. Green, Ian O. Ellis, Frank Entschladen Published in: Oncotarget DOI: 10.18632/oncotarget.197 ABSTRACT Laboratory models show that the beta-blocker, propranolol, can inhibit norepinephrine-induced breast cancer cell migration. We hypothesised that breast cancer patients receiving beta-blockers for hypertension would show reduced metastasis and improved clinical outcome. Three patient subgroups were identified from the medical records of 466 consecutive female patients (median age 57, range 28-71) with operable breast cancer and follow-up (>10 years). Two subgroups comprised 43 and 49 hypertensive patients treated with beta-blockers or other antihypertensives respectively, prior to cancer diagnosis. 374 patients formed a non-hypertensive control group. Metastasis development, disease free interval, tumour recurrence and hazards risk were statistically compared between groups. Kaplan-Meier plots were used to model survival and DM. Beta-blocker treated patients showed a significant reduction in metastasis development (p=0.026), tumour recurrence (p=0.001), and longer disease free interval (p=0.01). In addition, there was a 57% reduced risk of metastasis (Hazards ratio=0.430; 95% CI=0.200-0.926, p=0.031), and a 71% reduction in breast cancer mortality after 10 years (Hazards ratio=0.291; 95% CI=0.119-0.715, p=0.007). This proof-of-principle study showed beta-blocker therapy significantly reduces distant metastases, cancer recurrence, and cancer-specific mortality in breast cancer patients suggesting a novel role for beta-blocker therapy. A larger epidemiological study leading to randomised clinical trials is needed for breast and other cancer types including colon, prostate and ovary. INTRODUCTION Although an estimated 38,000 [1] patients are diagnosed with breast cancer in the US each year death rates are declining in part due to adjuvant therapies including the use of ER-antagonists and anti-HER2 (trastuzumab) therapy [2-4]. Nonetheless, approximately 30% of treated BC patients develop distant metastases [5] and these significantly account for 90% of breast cancer deaths [6]. Consequently, therapeutic strategies are needed that target metastasis [7,8]. Metastasis formation involves migration of malignant cells from the primary tumour via lymphatic or blood vessel routes with the process being tightly regulated by exogenous cell signalling molecules, including ligands to G protein-coupled receptors (GPCRs) such as neurotransmitters and chemokines [9,10]. In previous in vitro cell migration studies we have shown that the stress catecholamine hormone norepinephrine is a potent inducer of migratory activity in carcinoma cell lines of colon [11], prostate [12], ovarian cancer cells [13] and breast [14] tissue origin, and this finding has been confirmed in a mouse model [15]. Moreover, we have shown that cell migration is mediated by adrenergic receptors (AR) and that the process is inhibited by the beta-blocker adrenergic receptor antagonist drug propranolol which is non-selective for β1AR and β2AR [11,12,15]. Additional support for the therapeutic benefit of beta-blockers is provided by recent studies showing propranolol can reduce proliferation in human pancreatic cell lines [16,17]. Beta-blocker drugs along with ACE-inhibitors, calcium channel antagonists, imidazoline receptor antagonists, and diuretics are clinically well characterized for the therapeutic treatment of hypertension and are proven in reducing life-threatening cerebrovascular events [18,19]. Epidemiologic studies confirm that beta-blocker treatment per se has no effect in causing or promoting cancer growth giving reassurance for their continued clinical use [20,21]. In the present study we hypothesised that patients started on and maintained with antihypertensive beta-blocker therapy prior to their breast cancer diagnosis would show reduced distant metastasis formation compared to non-hypertensive breast cancer patients or those treated with other antihypertensive drugs. RESULTS Clinical Correlations in Patients Treated with Beta-Blocker Drugs compared to other Hypertensive and Non-hypertensive Breast Cancer Patients Data was obtained for 466 breast cancer patients used in this study and their characteristics are shown in Tables 1a-d. A total of 92 (19.7%) patients had hypertension diagnosed prior to breast cancer diagnosis and were therapeutically treated using a range of antihypertensives including beta-blockers, ACE inhibitors, Ca2+ antagonists, imidazoline receptor antagonists or diuretics (Table 2). In particular, 43/92 (46.7%) of this hypertensive subgroup (median age 57 years, range 39-69) received beta-blocker drugs while the remaining 49/92 (53.3%) patients received other antihypertensive drugs. The latter group significantly differed in showing increased median age of 62 years (range 47-70) compared to the non-hypertensive patient subgroup whose median age was 54.5 years (range 28-71). In addition, the non-beta-blocker treated antihypertensive subgroup contained an increased proportion of post-menopausal patients (Table 1c) Otherwise, no significant difference was seen in tumour stage, tumour size, grade, type, vascular invasion, Nottingham Prognostic Index (NPI) or AT between the three patient subgroups. [Table: Characteristics for breast cancer patients therapeutically treated with beta-blockers (BB) compared to control breast cancer (BC) patients, excluding patients treated with other types of antihypertensive drugs] [Table: Characteristics for breast cancer patients therapeutically treated with beta-blockers (BB) compared to breast cancer (BC) patients treated with other antihypertensive drugs] [Table: Characteristics for breast cancer patients therapeutically treated with antihypertensive drugs (excluding beta blockers) compared to control breast cancer (BC) patients] [Table: Characteristics for breast cancer patients therapeutically treated with beta-blockers (BB) compared to all other patients including those receiving other antihypertensive drug treatment] [Table: Beta-blocker and other therapeutic drugs were used to treat breast cancer patients for pre-existing hypertension] Patients receiving beta-blockers showed a significant reduction in formation of distant metastasis (χ2=4.986, p=0.026) and tumour recurrence (χ2=13.091, p=0.001) compared to non-hypertensive BC control patients (Table 3). [Table: Two hypertensive breast cancer (BC) patient groups comprising those treated with beta-blockers and non-beta blocker antihypertensive drugs were compared with a non-hypertensive non-treated BC group for formation of distant metastases] Hypertensive Breast Cancer Patients Treated with Beta-Blockers Compared with Other Antihypertensive Drugs Beta-blocker treated breast cancer patients differed significantly to patients receiving other antihypertensives (χ2=4.852, p=0.028) in showing reduced development of distant metastasis (5/43 (11.6%)) compared to their counterparts (15/49 (30.6%)) (Table 3). In addition, the beta-blocker treated subgroup showed significantly reduced tumour recurrence (χ2=7.264, p=0.026; Table 1b). PATIENT OUTCOME Univariate analysis: Kaplan-Meier modelling with log rank testing showed beta-blocker treated patients had longer distant metastasis-free interval (Log rank (LR)=5.208, p=0.022) (Fig 1a) and longer breast cancer specific survival (LR=6.479, p=0.011) (Fig 1b), and longer disease free interval (LR=6.658, p=0.011) when compared to non-treated breast cancer patients. [Figure: a: Hypertensive BC patients therapeutically treated with beta-blockers showed significantly (p=0.022) longer times before acquiring metastases compared to non-treated patientsb. Hypertensive BC patients receiving beta-blocker therapy showed significantly (p=0.011) improved 10 year survival rates compared to non-treated patients.] Multivariate analysis: A multivariate Cox hazard model was used to determine the hazard ratio (HR) for predicting breast cancer specific survival and distant metastasis risk in patients receiving beta-blocker treatment compared to other significant breast cancer variables including tumour size, stage and grade. Patients receiving beta-blocker treatment had a 71% reduced risk of cancer-associated mortality (HR=0.291, CI= 0.119-0.715, p=0.007). In addition, beta-blocker treated patients showed a 57% risk reduction in developing distant metastasis (HR=0.430, CI= 0.200-0.926, p=0.031; Table 4) compared to non-treated breast cancer patients. [Table: The effect of beta-blocker treatment on breast cancer specific survival (BCSS) and distant metastasis (DM) formation was compared with tumour size, grade and stage to determine the relative risk (Hazard Ratios (HR)) in BC patients] DISCUSSION Evidence of the biological mechanism between stress hormones and tumour cell migration Tumour metastasis is a complex process and is associated with generally poor clinical